secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0000882095-26-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges
--------------------------------------------------------------------------------

- Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).
- GAAP diluted EPS $1.61 (vs $1.04); non-GAAP $2.03 (vs $1.81) — both up YoY.
- Full-year product sales guidance raised to $30.0-30.4B; GAAP EPS guidance cut to $(3.25)-(2.85) from $6.75-7.15.
- EPS guidance reduction driven by anticipated $11.5B IPR&D charges for Arcellx, Ouro and Tubulis acquisitions.
- Cell Therapy sales down 12% to $407M; Trodelvy up 37% to $402M; Veklury down 52% to $144M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/0000882095-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/gild-20260507.htm
  HTML page:      https://secwatch.observer/filing/0000882095-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer